Citi analyst Daniel Grosslight is opening a "Catalyst Watch" on GoodRx as he thinks there is upside to consensus numbers given the intensifying flu, RSV, and COVID season this winter. The analyst, who thinks GoodRx is likely to beat expectations in Q4 of FY22 and Q1 of FY23, has a Buy rating and $7 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GDRX: